Nothing Special   »   [go: up one dir, main page]

WO2005117941A3 - Methods and compositions for the treatment of polycystic diseases - Google Patents

Methods and compositions for the treatment of polycystic diseases Download PDF

Info

Publication number
WO2005117941A3
WO2005117941A3 PCT/US2005/014982 US2005014982W WO2005117941A3 WO 2005117941 A3 WO2005117941 A3 WO 2005117941A3 US 2005014982 W US2005014982 W US 2005014982W WO 2005117941 A3 WO2005117941 A3 WO 2005117941A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
gene
treat
tissue
Prior art date
Application number
PCT/US2005/014982
Other languages
French (fr)
Other versions
WO2005117941A2 (en
Inventor
Oxana Beskrovnaya
Herve Husson
Original Assignee
Genzyme Corp
Oxana Beskrovnaya
Herve Husson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Oxana Beskrovnaya, Herve Husson filed Critical Genzyme Corp
Priority to JP2007511046A priority Critical patent/JP2007535562A/en
Priority to BRPI0510367-3A priority patent/BRPI0510367A/en
Priority to CA002564092A priority patent/CA2564092A1/en
Priority to MXPA06012446A priority patent/MXPA06012446A/en
Priority to EP05804799A priority patent/EP1740221A4/en
Publication of WO2005117941A2 publication Critical patent/WO2005117941A2/en
Publication of WO2005117941A3 publication Critical patent/WO2005117941A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides compositions and methods to diagnose and treat polycystic disorders by inhibiting the biological activity of a gene now correlated with appearance of this disorder. By way of illustrative only, the Connective Tissue Growth Factor (CTGF) gene is an example of such a gene. Also provided by this invention are compositions and methods to treat or ameliorate abnormal cystic lesions and diseases associated with the formation of cysts in tissue. The methods and compositions treat and ameliorate pathological cyst formation in tissue by inhibiting or augmenting gene expression or the biological activity of its gene expression product or its receptor.
PCT/US2005/014982 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases WO2005117941A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007511046A JP2007535562A (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic disease
BRPI0510367-3A BRPI0510367A (en) 2004-04-29 2005-04-29 methods and compositions for the treatment of polycystic diseases
CA002564092A CA2564092A1 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases
MXPA06012446A MXPA06012446A (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases.
EP05804799A EP1740221A4 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56667004P 2004-04-29 2004-04-29
US60/566,670 2004-04-29
US59038504P 2004-07-22 2004-07-22
US60/590,385 2004-07-22

Publications (2)

Publication Number Publication Date
WO2005117941A2 WO2005117941A2 (en) 2005-12-15
WO2005117941A3 true WO2005117941A3 (en) 2006-05-18

Family

ID=35463346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014982 WO2005117941A2 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Country Status (6)

Country Link
EP (1) EP1740221A4 (en)
JP (1) JP2007535562A (en)
BR (1) BRPI0510367A (en)
CA (1) CA2564092A1 (en)
MX (1) MXPA06012446A (en)
WO (1) WO2005117941A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406063T3 (en) 2005-12-08 2013-06-05 Medarex, Inc. Human monoclonal antibodies against the protein Tyrosine Kinase 7 (PTK7) and its use
EP1808694A1 (en) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2617423A1 (en) * 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
US8252762B2 (en) 2008-08-25 2012-08-28 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
JP6177692B2 (en) 2011-02-02 2017-08-09 エクスカリアード・ファーマシューティカルズ，インク Treatment of keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
JP5995207B2 (en) * 2014-11-28 2016-09-21 学校法人 学習院 Boron-containing porphyrin derivatives
KR102288447B1 (en) * 2018-12-28 2021-08-10 서울대학교산학협력단 Composition for diagnosing polycystic kidney disease comprising agent for detecting CTGF and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882881A (en) * 1992-09-25 1999-03-16 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043335A4 (en) * 1997-12-25 2005-08-31 Japan Tobacco Inc Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882881A (en) * 1992-09-25 1999-03-16 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ABDEL WAHAB ET AL, BIOCHEM J., vol. 359, 2001, pages 77 - 87, XP002372274 *
BLOM ET AL, MATRIX BIOLOGY., vol. 21, 2002, pages 473 - 482, XP003003087 *
DUNCAN ET AL, FASEB J., vol. 13, 1999, pages 1774 - 1786, XP000916666 *
GATTONE V H, RICKER J L: "INTERVENTIONSIN POLYCYSTIC KIDNEY DISEASE USING ANTISENSE OLIGONUCLEOTIDES", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY.ANNUAL MEETING. ABSTRACTS OF PAPERS., XX, XX, vol. 16, no. 5, 24 April 2002 (2002-04-24), XX, pages A1097, ABSTRACT 781.2, XP008070521 *
GATTONE., CURRENT OPINION IN PHARMACOLOGY., vol. 5, 2005, pages 535 - 542, XP005059129 *
HUSSON ET AL, GENOMICS., vol. 84, 2004, pages 497 - 510, XP004525497 *
RICKER ET AL, KIDNEY INTERNATIONAL., vol. 61, 2002, pages 125 - 131, XP003003086 *
See also references of EP1740221A4 *
SHIMO ET AL, J BIOCHEM., vol. 124, 1998, pages 130 - 134, XP009009314 *
UCHIO ET AL, WOUND REPARING REGEN., vol. 12, no. 1, January 2004 (2004-01-01) - February 2004 (2004-02-01), pages 60 - 66, XP008070624 *

Also Published As

Publication number Publication date
MXPA06012446A (en) 2007-01-17
JP2007535562A (en) 2007-12-06
CA2564092A1 (en) 2005-12-15
BRPI0510367A (en) 2007-11-06
EP1740221A4 (en) 2009-01-07
WO2005117941A2 (en) 2005-12-15
EP1740221A2 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
WO2021178237A3 (en) Oligonucleotide compositions and methods thereof
WO2007061750A3 (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2006040153A3 (en) Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
WO2007021647A3 (en) Method for treating myocradial rupture
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2001001748A3 (en) Peptide compounds that bind her2
EP2402443A3 (en) Therapeutic uses of inhibitors of rtp801
WO2001056567A8 (en) 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
WO2006108582A3 (en) Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
WO2006128029A3 (en) Production of osteoclasts from adipose tissues
WO2007106577A3 (en) Gelsolin in the treatment and diagnosis of neurological disease
WO2007117438A3 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2004014222A3 (en) Diagnosis and treatment of tuberous sclerosis
WO2006127152A3 (en) Methods for making and using regulatory t cells
WO2005117941A3 (en) Methods and compositions for the treatment of polycystic diseases
WO2007120955A3 (en) Genes affecting human memory performance
WO2008125902A3 (en) Peripheral and neural inflammatory crosstalk
EP1441724B8 (en) Methods of increasing endogenous testosterone levels
WO2002092858A3 (en) Methods of screening for disease
WO2004091646A3 (en) Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2001096873A3 (en) Method for identifying apoptosis-modified proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005804799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2564092

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012446

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007511046

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 3566/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580021831.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005804799

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0510367

Country of ref document: BR